39 min listen
CAR T-cells For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D.
CAR T-cells For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D.
ratings:
Length:
56 minutes
Released:
Mar 7, 2022
Format:
Podcast episode
Description
While success has been seen in animal models, solid tumors have proved a vexing challenge for CAR T-cell therapies. On this week's episode of the Business of Biotech, we're joined by Anixa Biosciences Chairman, President, & CEO Amit Kumar, Ph.D. Dr. Kumar shares on the company's progress with a CAR T-cell therapy that aims to attack both tumor cells and the tumor vasculature, in hopes that it might be the first to destroy solid ovarian cancers. Discover more on recent developments in autologous and allogeneic CAR T-cell therapies in this column from Mustang Bio at BioProcessOnline.com.
Released:
Mar 7, 2022
Format:
Podcast episode
Titles in the series (100)
001: The Business Of Biotech: Allan Shaw by Business Of Biotech